α-Methylacyl-coenzyme A racemase (AMACR, p504s) is a marker to distinguish malignant melanomas from dysplastic nevi and melanocytic nevi
详细信息 查看全文
- 作者：M. Abbas ; E. M. Ploch ; J. Wehling ; E. Schipper ; S. Janciauskiene…
- 关键词：α ; Methylacyl ; CoA racemase ; p16Ink4a ; Benign and dysplastic nevi ; Melanoma ; Immunocytochemistry
- 刊名：Tumor Biology
- 出版年：2014
- 出版时间：December 2014
- 年：2014
- 卷：35
- 期：12
- 页码：12015-12020
- 全文大小：1,213 KB
- 参考文献：1. Gandini S, Sera F, Cattaruzza MS, Pasquini P, Picconi O, Boyle P, et al. Meta-analysis of risk factors for cutaneous melanoma: II. Sun exposure. Eur J Cancer. 2005;41:45-0. CrossRef
2. Elder DE, Clark WH, Elenitsas R, Guerry D, Halpern AC. The early and intermediate precursor lesions of tumor progression in the melanocytic system: common acquired nevi and atypical (dysplastic) nevi. Semin Diagn Pathol. 1993;10:18-5.
3. Elder D. Benign pigmented lesions and malignant melanoma. In: Elder D, editor. Lever’s histopathology of the skin. 10th ed. Philadelphia: Lippincott Williams & Wilkins; 2006. p. 699-89.
4. Rivers JK, Cockerell CJ, McBride A, Kopf AW. Quantification of histologic features of dysplastic nevi. Am J Dermatopathol. 1990;12:42-0. CrossRef
5. Kriegl L, Neumann J, Vieth M, Greten FR, Reu S, Jung A, et al. Up and downregulation of p16(Ink4a) expression in BRAF-mutated polyps/adenomas indicates a senescence barrier in the serrated route to colon cancer. Mod Pathol. 2011;24:1015-2. CrossRef
6. Ferdinandusse S, Denis S, IJlst L, Dacremont G, Waterham HR, Wanders RJ. Subcellular localization and physiological role of alpha-methylacyl-CoA racemase. J Lipid Res. 2000;41:1890-.
7. George E, Polissar NL, Wick M. Immunohistochemical evaluation of 16INK4A, E-cadherin, and cyclin D1 expression in melanoma and Spitz tumors. Am J Clin Pathol. 2010;133:370-. CrossRef
8. Krengel S, Grotelüschen F, Bartsch S, Tronnier M. Cadherin expression pattern in melanocytic tumors more likely depends on the melanocyte environment than on tumor cell progression. J Cutan Pathol. 2004;1:1-. CrossRef
9. Mengel M, von Wasielewski R, Wiese B, Rudiger T, Muller-Hermelink HK, Kreipe H. Inter-laboratory and inter-observer reproducibility of immunohistochemical assessment of the Ki-67 labelling index in a large multi-centre trial. J Pathol. 2002;198:292-. CrossRef
10. Tsao H, Bevona C, Goggins W, Quinn T. The transformation rate of moles (melanocytic nevi) into cutaneous melanoma: a population-based estimate. Arch Dermatol. 2003;139:282-. CrossRef
11. Dayi N, Baba HA, Schmid KW, Schmitz KJ. Increased expression of α-methylacyl-coenzyme A racemase (AMACR; p504s) and p16 in distal hyperplastic polyps. Diagn Pathol. 2013;8:178-4. CrossRef
12. Salava A, Ranki A. Saksela O [Dysplastic melanocytic nevus]. Duodecim. 2010;126:2492-01.
13. Kang S, Barnhill RL, Mihm Jr MC, Fitzpatrick TB, Sober AJ. Melanoma risk in individuals with clinically atypical nevi. Arch Dermatol. 1994;130:999-001. CrossRef
14. Jiang Z, Li C, Fischer A, Dresser K, Woda BA. Using an AMACR (P504S)/ 34betaE12/p63 cocktail for the detection of small focal prostate carcinoma in needle biopsy specimens. Am J Clin Pathol. 2005;123:231-. CrossRef
15. Snover DC. Serrated polyps of the large intestine. Semin Diagn Pathol. 2005;22:301-. CrossRef
16. Fujimori Y, Fujimori T, Imura J, Sugai T, Yao T, Wada R, Ajioka Y, Ohkura Y. An assessment of the diagnostic criteria for sessile serrated adenoma/ polyps: SSA/Ps using image processing software analysis for Ki67 immunohistochemistry. Diagn Pathol. 2012; 59.
17. Chin L, Garraway LA, Fisher DE. Malignant melanoma: genetics and therapeutics in the genomic era. Genes Dev. 2006;20:2149-2. CrossRef
18. Sparrow LE, Eldon MJ, English DR, Heenan PJ. P16 and p21WAF1 protein expression in melanocytic tumors by immunohistochemistry. Am J Dermatopathol. 1998;20:255-1.
文摘
Routinely processed skin biopsies are still the mainstay for the diagnosis of melanocytic skin neoplasms (MSNs) and are considered the “gold standard-for individual patient management and clinical trials. The diagnostic challenge of melanocytic lesions of the skin prompts histopathologists to consider new diagnostic tools; among these, immunohistochemistry. We aimed to find putative new immunohistochemical markers, which can supplement the histological criteria used to detect dysplasia. In this immunohistochemical study, we chose a panel of promising biomarkers which could potentially differentiate between different MSN entities. These included α-methylacyl-coenzyme A racemase (AMACR; p504s), which is involved in the degradation of branched chained fatty acid derivates. We analysed a cohort of benign nevi and malignant melanomas. The design of the study included 78 melanocytic skin neoplasms (26 malignant melanomas and 52 benign nevi) in a tissue microarray. Immunohistochemistry of cyclin-dependent kinase inhibitor 2A (p16Ink4a), methylacyl-coenzyme A racemase (AMACR), cyclin D1, and E-cadherin was performed and assessed. We have observed that the p16Ink4a, AMACR, cyclin D1, and E-cadherin showed no exclusive staining for nevi or melanomas. However, a significant overexpression of AMACR was found in malignant melanomas compared to benign nevi. AMACR overexpression was also associated with an increased p16Ink4a staining. Our results suggest AMACR as an immunohistochemical marker for distinguishing malignant melanomas and dysplastic nevi from conventional melanocytic nevi.